Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today announced the availability of TECNIS Synergy and TECNIS Synergy Toric II IOLs in the United States and Canada.
| The next-generation presbyopia-correcting intraocular lens (PC-IOL) offers cataract patients the widest^ range of continuous^^ vision and best near vision among leading PC-IOLs^^^^ 1,2,3,4,5 Now available in the U.S. and Canada, TECNIS Synergy PC-IOLs offers cataract patients the opportunity to experience excellent outcomes, with 9 out of 10 patients surveyed reporting they didn’t wear glasses following treatment6 ^^^ Throughout Cataract Awareness Month in June, Johnson & Johnson Vision is providing education about the symptoms of cataracts and the many treatments options available ^vs Acrysof® IQ PanOptix® IOL, TECNIS Symfony™ IOL, TECNIS® Multifocal IOL (United States), vs. Acrysof® IQ PanOptix® IOL, AT Lisa Trifocal IOL and FineVision IOL (Canada). Based on comparison of DFU defocus curves and a head to head clinical study vs. Acrysof® IQ PanOptix® IOL. ^^Continuous 20/32 or better ^^^Based on interim 6-months post-operative data ^^^^vs. Acrysof® IQ PanOptix® IOL SANTA ANA, Calif., June 23, 2021 /PRNewswire/ -- Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today announced the availability of TECNIS Synergy and TECNIS Synergy Toric II IOLs in the United States and Canada. These next-generation PC-IOLs combine the best of extended depth of focus and multifocal technologies to deliver the widest^ range of continuous^^ vision and the best near vision among leading PC-IOLs, ^^^^ 4 without the visual gaps seen with some existing multifocal technologies. 1, 2, 3, 5 Ophthalmologists across North America are now able to use this breakthrough PC-IOL to help treat their cataract patients, offering them the opportunity to experience excellent outcomes.^ ^^^6 Experience the interactive Multichannel News Release here: Cataracts are the leading cause of preventable blindness worldwide, impacting more than 100 million eyes, with more than 90% of people developing cataracts by the age of 65.7,8 Most people will develop cataracts at some point in their life, and modern cataract surgery is a safe and effective treatment that has a success rate of nearly 98%.9 However, in the U.S., 22% of people with cataracts say that their lack of knowledge of the procedure is a barrier to them seeking treatment,10 with many not realizing that there are intraocular lenses (IOL) available that may give them freedom from glasses. Today’s 55 – 64-year-olds are also using digital devices at much higher rates, and there’s been a rapid increase in adoption of LED lighting, requiring an IOL that delivers high-quality vision, at all distances, in all lighting conditions. “My cataract patients are getting younger, have more active lifestyles, and want to be able to see their smartphones in the day and their menus at dinner,” said Dr. Vance Thompson, Vance Thompson Vision in Sioux Falls, South Dakota.*** “They have high expectations for their vision following cataract surgery, and the patients I’ve implanted with TECNIS Synergy™ IOL have not been let down. This new lens has provided the wide range of continuous^^ vision patients are looking for, with great image contrast throughout the day, even in low lighting conditions.” ^^^^11 “I’ve been using the TECNIS Synergy IOL for the past year and have been extremely impressed with the wide range of continuous^^ vision it provides,” said Dr. Sheldon Herzig, Herzig Eye Institute in Toronto and Ottawa.*** “This lens has provided the best near^^^ 4 vision for my patients, and most of my patients have said they have not used their glasses following surgery.6 I implanted my first TECNIS Synergy Toric II last week, which also corrects my patients’ astigmatism to improve both distance and near vision.” The TECNIS Synergy IOL is built on the legacy TECNIS platform and delivers excellent performance, image contrast, and patient outcomes:
“Around the world, the excitement for TECNIS Synergy PC-IOLs has been incredible and we’re proud of the excellent outcomes this innovation has delivered for patients,” said Sandor Palfi, Commercial Vice President of the Americas, Surgical at Johnson & Johnson Vision.**** “We are delighted to bring the most advanced TECNIS IOL to North America with TECNIS Synergy. Surgeons across the U.S. and Canada now have access to an IOL that will meet the needs of today’s cataract patients, who don’t want their life or their vision to be limited by their IOL.” 6,11 ^^^ The TECNIS Synergy PC-IOL was first launched in Europe and Asia Pacific in 2019 and is now available in Latin America, Canada, and the United States. Ophthalmologists in North America can learn more about the TECNIS Synergy PC-IOL portfolio at the Annual Canadian Ophthalmological Society virtual meeting later this week, and at the American Society of Cataract & Refractive Surgeons Annual Meeting in Las Vegas in July. In addition to bringing the full TECNIS Synergy PC-IOL portfolio to the market in North America this month, Johnson & Johnson Vision is providing education to patients and caregivers about the symptoms of cataracts and the treatments options. In honor of Cataract Awareness Month, Johnson & Johnson is sharing cataract patient stories and information from ophthalmologist through various media, digital, and social media channels. For more information, patients and their caregivers are encouraged to visit beyondcataracts.com and follow Johnson & Johnson Vision on @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook. ^vs Acrysof® IQ PanOptix® IOL, TECNIS Symfony™ IOL, TECNIS® Multifocal IOL (United States), vs. Acrysof® IQ PanOptix® IOL, AT Lisa Trifocal IOL and FineVision IOL (Canada). Based on comparison of DFU defocus curves and a head to head clinical study vs. Acrysof® IQ PanOptix® IOL. About The TECNIS® Family of IOLs About Johnson & Johnson Vision About Johnson & Johnson Medical Devices Companies Cautions Concerning Forward-Looking Statements ‡Competitor platforms included are Hoya, Alcon & B&L Acrylic INDICATIONS and IMPORTANT SAFETY INFORMATION FOR TECNIS Synergy™ IOL with TECNIS Simplicity™ Delivery System, Model DFR00V and TECNIS Synergy™ Toric II IOL with TECNIS Simplicity™ Delivery System, Models DFW150, DFW225, DFW300, DFW375, in the United States INDICATIONS PRECAUTIONS INDICATIONS and IMPORTANT SAFETY INFORMATION FOR TECNIS SYNERGY™ TORIC II OPTIBLUE IOL WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODELs DFW100, DFW150, DFW225, DFW300 AND DFW375 INDICATIONS FOR USE: The TECNIS Simplicity™ Delivery System is used to fold and assist in inserting the TECNIS Synergy™ Toric II OptiBlue™ IOLs which are indicated for primary implantation for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with or without presbyopia, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing vision far through near, a reduction of residual refractive cylinder and reduced spectacle dependence across a range of distances. PRECAUTIONS: Recent contact lens usage may affect the patient’s refraction; therefore, in contact lens wearers, surgeons should establish corneal stability without contact lenses prior to determining IOL power. Prior to implanting, examine the lens package for proper lens model, dioptric power, and expiration date. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. Care should be taken to achieve centration of the intraocular lens. When the insertion system is used improperly, the haptics of the IOL may become broken. Please refer to the specific instructions for use provided with the insertion instrument or system. Safety and effectiveness in patients 21 years or younger have not been established in clinical studies. The intraocular pressure of implanted patients with glaucoma should be carefully monitored for postoperative changes. WARNINGS: Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio. The lens should be placed entirely in the capsular bag. Do not place the lens in the ciliary sulcus. Well-informed patients with well-defined visual needs and preferences should be selected for lens model ZFW implantation. The patients should be informed of the possibility of visual effects (such as halo or glare) in nighttime or poor visibility conditions. Patients with a predicted postoperative astigmatism greater than 1.0 diopter may not be suitable candidates for lens model ZFW implantation since they may not fully benefit in terms of potential spectacle independence. Patients may perceive these visual effects as an annoyance or hindrance, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. The lens model ZFW may affect image quality and lead to some reduction of contrast sensitivity compared to a monofocal lens. Therefore, patients should exercise caution when driving at night or in poor visibility conditions. Rotation of toric lens model ZFW from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible prior to lens encapsulation. Carefully remove all viscoelastic from the capsular bag. Residual viscoelastic may allow the lens to rotate, causing misalignment of the toric lens model ZFW with the intended axis of placement. ADVERSE EVENTS: Potential adverse events during or following cataract surgery with implantation of the IOL may include but are not limited to: Endophthalmitis/intraocular infection, IOL dislocation, Persistent cystoid macular edema, Persistent corneal stromal edema, Persistent raised intraocular pressure (IOP) requiring treatment, Secondary surgical intervention (including implant repositioning, removal, AC tap, or other surgical procedure). Adverse events can lead to permanent visual impairment and may require secondary surgical intervention, including intraocular lens exchange or explantation. ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information. INDICATIONS and IMPORTANT SAFETY INFORMATION FOR TECNIS SYNERGY™ OPTIBLUE® WITH TECNIS SIMPLICITY™ DELIVERY SYSTEM, MODEL DFR00V, IN CANADA INDICATIONS FOR USE: The TECNIS Simplicity™ Delivery System is used to fold and assist in inserting the TECNIS Synergy™ OptiBlue® IOL which is indicated for primary implantation for the visual correction of aphakia in adult patients with or without presbyopia, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing vision far through near and reduced spectacle dependence across a range of distances. The lens is intended to be placed in the capsular bag. PRECAUTIONS: Recent contact lens usage may affect the patient’s refraction; therefore, in contact lens wearers, surgeons should establish corneal stability without contact lenses prior to determining IOL power. Prior to implanting, examine the lens package for proper lens model, dioptric power, and expiration date. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. Care should be taken to achieve centration of the intraocular lens. When the insertion system is used improperly, the haptics of the IOL may become broken. Please refer to the specific instructions for use provided with the insertion instrument or system. Safety and effectiveness in patients 21 years or younger have not been established in clinical studies. The intraocular pressure of implanted patients with glaucoma should be carefully monitored for postoperative changes. WARNINGS: Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio. The lens model ZFR00V should be placed entirely in the capsular bag. Do not place the lens in the ciliary sulcus. Well-informed patients with well-defined visual needs and preferences should be selected for lens model ZFR00V implantation. The patients should be informed of the possibility of visual effects (such as halo or glare) in nighttime or poor visibility conditions. Patients may perceive these visual effects as an annoyance or hindrance, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. Patients with a predicted postoperative astigmatism greater than 1.0 diopter may not be suitable candidates for lens model ZFR00V implantation since they may not fully benefit in terms of potential spectacle independence. The lens model ZFR00V may affect image quality and lead to some reduction of contrast sensitivity compared to a monofocal lens. Therefore, patients should exercise caution when driving at night or in poor visibility conditions. ADVERSE EVENTS: Potential adverse events during or following cataract surgery with implantation of the IOL may include but are not limited to: Endophthalmitis/intraocular infection, IOL dislocation, Persistent cystoid macular edema, Persistent corneal stromal edema, Persistent raised intraocular pressure (IOP) requiring treatment, Secondary surgical intervention (including implant repositioning, removal, AC tap, or other surgical procedure). Adverse events can lead to permanent visual impairment and may require secondary surgical intervention, including intraocular lens exchange or explantation. *Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both. **The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment. ***Dr. Vance Thompson and Dr. Sheldon Herzig are paid consultants to Johnson & Johnson Vision. ****Sandor Palfi is an employee of Johnson & Johnson Vision, Inc., serving as Commercial Vice President of the Americas, with oversight for Surgical Vision in the U.S., Latin America and Canada regions. © Johnson & Johnson Vision, 2021. All rights reserved.
Media Contact: Investor Contact:
SOURCE Johnson & Johnson Vision |
View original content:
